Managing irritable bowel syndrome (IBS) just got a potential new ally. A prospective study of over 400 adults found that an oral enzyme supplement targeting three FODMAP groups — fructans, lactose, and galacto-oligosaccharides — meaningfully reduced IBS symptom severity over four weeks. Presented at the American College of Gastroenterology annual meeting, the findings offer a possible alternative or complement to the notoriously difficult-to-follow low-FODMAP diet.

The enzyme blend showed consistent benefits across all IBS subtypes, and improvements were seen even among patients already on a low-FODMAP diet — suggesting additive value. Researchers are hopeful the approach could eventually help patients "liberalize" their diets without sacrificing symptom control. That said, the study lacked a placebo group and had a short follow-up, so randomized trials are the necessary next step.

By the Numbers:

• Mean IBS Symptom Severity Score dropped from 269.7 → 167.3 points over 4 weeks
• 69% of patients achieved a clinically meaningful improvement (≥50-point reduction)
• 52% achieved a ≥100-point reduction
• Pain frequency fell from 5.9 to 3.9 days out of every 10

Why it matters: Adherence to the low-FODMAP diet is a major barrier for IBS patients. An enzyme-based strategy could offer a simpler, more sustainable path to symptom relief — if future randomized trials confirm these early results.